EGFR + NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight 2026" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the EGFR + NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in EGFR + NSCLC research @ EGFR + NSCLC Pipeline Outlook [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the EGFR + NSCLC Pipeline Report

* On March 20, 2026- Merck Sharp & Dohme LLC announced a study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
* On March 19, 2026- Suzhou Suncadia Biopharmaceuticals Co. Ltd . initiated a phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.
* On March 12, 2026- Bayer conducted a study will take the study treatment BAY2927088 in 3-week periods called "cycles". They will in general take BAY2927088 once or twice daily as a liquid/tablet by mouth until their cancer gets worse, they have medical problems, they leave the study, or the study is terminated. Participants will have no more than 5 visits per cycle.
* On March 12, 2026- Beijing Biotech announced a Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors co-express at least two of the following antigens: Mesothelin (MSLN), EGFR, and HER2/ERBB2.
* On March 10, 2026- Taiho Oncology Inc . announced a study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
* On March 03, 2026- Summit Therapeutics initiated a Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
* DelveInsight's EGFR + NSCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for EGFR + NSCLC treatment.
* The leading EGFR + NSCLC Companies such as Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
* Promising EGFR+NSCLC Pipeline Therapies such as IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib , and others.

Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments @ EGFR + NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

EGFR Non-Small Cell Lung Cancer (NSCLC) Overview

EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) is a subtype of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. This receptor plays a critical role in cell growth and division. Mutations in EGFR lead to uncontrolled cell proliferation, contributing to cancer development. EGFR mutations are present in approximately 10-15% of NSCLC cases in Western populations and around 30-50% in Asian populations. This subtype of lung cancer is most commonly found in non-smokers, women, and patients with adenocarcinoma, a form of NSCLC.

EGFR + NSCLC Emerging Drugs Profile

* CLN-081: Cullinan Oncology

CLN-081 is a novel irreversible Epidermal Growth Factor Receptor (EFGR) inhibitor. It is administered through oral route, and is developed by Cullinan Oncology. The drug is being developed in association with Taiho Pharmaceuticals. The drug is currently being investigated in the Phase III stage of development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).

* BPI-361175: Betta Pharmaceuticals

BPI-361175 is a novel, oral, highly potent and selective 4th generation EGFR inhibitor developed by Betta Pharmaceutical Co., Ltd. The new chemical entity targets EGFR C797S mutation and other EGFR related mutations that are resistant to 3rd generation EGFR TKI in non-small cell lung cancer (NSCLC) and other solid tumors. It shows excellent inhibitory effect and selectivity in vitro assay and exhibits significant anti-tumor activity in a variety of xenograft models harboring EGFR C797S or other related mutations. The IND application of BPI-361175 has been approved by NMPA. Currently, the drug is the Phase I/II stage of its development for the treatment of Non-small Cell Lung Cancer.

* G1T38: G1 Therapeutics

G1T38 is an investigational, oral CDK4/6 inhibitor designed to be used along with other targeted therapies for various oncology indications. G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca's Tagrisso (osimertinib) in a Phase Ib/II clinical trial to treat patients suffering from EGFR mutation-positive non-small cell lung cancer (NSCLC). Currently, the drug is being evaluated in the Phase I/II stage in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer.

* JANX008: Janux Therapeutics

JANX008, is a TRACTr that targets Epidermal Growth Factor Receptor (EGFR), and is being developed by Janux Therapeutics for the treatment of various solid tumors including non-small cell lung cancer. According to preclinical studies, JANX008 showed potent cleavage dependent anti-tumor activity, with limited toxicities in healthy tissues or CRS. JANX008, is currently being evaluated in phase I clinical trial for the treatment of various solid tumors.

The EGFR + NSCLC Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of EGFR + NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR + NSCLC Treatment.
* EGFR + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* EGFR + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR + NSCLC market.

Learn more about EGFR + NSCLC Drugs opportunities in our groundbreaking EGFR + NSCLC Research @ EGFR + NSCLC Unmet Needs [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

EGFR + NSCLC Companies

Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.

EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

EGFR + NSCLC Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Stay informed about how we're transforming the future of oncology @ EGFR + NSCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the EGFR + NSCLC Pipeline Report

* Coverage- Global
* EGFR + NSCLC Companies- Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
* EGFR+NSCLC Pipeline Therapies- IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib , and others.
* EGFR + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* EGFR + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of EGFR + NSCLC Pipeline on our website, @ EGFR + NSCLC Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* EGFR Non-Small Cell Lung Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* EGFR Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CLN-081: Cullinan Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* BPI-361175: Betta Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
* EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products
* EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs
* EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Market Drivers and Barriers
* EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Future Perspectives and Conclusion
* EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views
* EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=egfr-nsclc-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.